Emerging Peptide Doping Threats Anti-Doping Labs Face
Peptides and Anti-Doping
63 peptide targets
Modern anti-doping laboratories can screen for 63 peptide-related substances in a single analytical run, covering GHRPs, GnRH analogs, and other prohibited compounds.
Judak et al., Journal of Chromatography B, 2021
Judak et al., Journal of Chromatography B, 2021
View as imageThe anti-doping fight against peptides is fundamentally different from fighting traditional steroids or stimulants. Peptides are short-lived in the body, often identical or near-identical to endogenous molecules, and increasingly available through gray-market suppliers who operate outside pharmaceutical regulation. Each year, the WADA Prohibited List expands its peptide coverage as new compounds emerge from research laboratories, wellness clinics, and underground chemistry. For the rationale behind why WADA bans peptides, the regulatory logic explains which categories are covered and why.
The challenge for anti-doping laboratories is not just detecting known peptides. It is anticipating which new peptides will be abused before they become widespread, developing validated detection methods fast enough to keep pace, and distinguishing exogenous administration from normal physiology.
Key Takeaways
- WADA added MOTS-c (a mitochondrial-derived peptide marketed for weight loss and performance) to the 2025 Prohibited List under metabolic modulators, alongside capromorelin and ibutamoren as named growth hormone secretagogue examples
- Modern anti-doping laboratories screen for 63 peptide-related substances using liquid chromatography-high resolution mass spectrometry (LC-HRMS), covering GHRPs, GnRH analogs, EPO mimetics, and other banned compounds (Judak et al., Journal of Chromatography B, 2021)
- Pegmolesatide, a PEGylated EPO-mimetic peptide approved in China in 2023, required development of entirely new detection methods using nanoLC-Q/Orbitrap mass spectrometry with EPO receptor-coupled magnetic beads (Liu et al., Drug Testing and Analysis, 2025)
- TB-500 (synthetic thymosin beta-4 fragment) can be detected at 0.02 ng/mL in plasma and 0.01 ng/mL in urine via LC-MS, including metabolites that extend the detection window (Ho et al., Journal of Chromatography A, 2012)
- Designer peptide modifications (glycine substitution, D-amino acid incorporation, PEGylation) are documented in seized doping materials and may evade standard screening panels
- The gap between peptide availability and validated detection methods is measured in months to years, creating windows of undetectable use
The Current Peptide Prohibited List
WADA's Prohibited List categorizes banned peptides across multiple sections:
S2 (Peptide Hormones, Growth Factors, Related Substances): This is the broadest category. It includes erythropoietin (EPO) and its mimetics (pegmolesatide, peginesatide), growth hormone (GH), insulin-like growth factor-1 (IGF-1), growth hormone releasing factors (GHRH, CJC-1295), GH secretagogues (GHRP-1 through GHRP-6, hexarelin, ipamorelin, ibutamoren/MK-677, capromorelin), and growth factors that affect muscle, tendon, or ligament protein synthesis (including thymosin beta-4/TB-500 and BPC-157).
S4 (Hormone and Metabolic Modulators): This section now includes MOTS-c (added 2025) as an AMP-activated protein kinase activator, alongside insulin and anti-estrogens.
S5 (Diuretics and Masking Agents): Desmopressin, a synthetic vasopressin analog, appears here because it can mask other doping agents by diluting urine samples.
The list structure uses a catch-all clause: "and other substances with similar chemical structure or similar biological effect(s)." This means novel peptides that are structurally or functionally similar to listed substances are prohibited even before they are explicitly named. For the detailed anti-doping status of BPC-157 and TB-500 specifically, these two peptides occupy a particularly complex regulatory position.
MOTS-c: The Newest Named Threat
MOTS-c is a mitochondrial-derived peptide encoded within the 12S rRNA gene. It activates AMP-activated protein kinase (AMPK), a cellular energy sensor that promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. In animal studies, MOTS-c improved exercise capacity, prevented age-related metabolic decline, and enhanced insulin sensitivity.
WADA added MOTS-c to the 2025 Prohibited List because it is actively marketed by anti-aging clinics and peptide vendors as a performance and body composition enhancer. Its theoretical mechanism of action, mimicking exercise-induced metabolic adaptations, makes it a plausible performance-enhancing agent even though human clinical trial data is sparse.
The detection challenge is that MOTS-c is an endogenous molecule. Every human produces it naturally. Anti-doping laboratories must distinguish between normal physiological levels and exogenous administration, likely requiring population-based reference ranges and potentially the Athlete Biological Passport approach rather than simple presence/absence testing.
Pegmolesatide: The Next-Generation EPO Mimetic
The EPO doping story has evolved from recombinant EPO (detectable by isoelectric focusing since 2000) to biosimilar EPOs to EPO-mimetic peptides. Pegmolesatide represents the latest iteration: a PEGylated homodimeric peptide that binds the EPO receptor, stimulating red blood cell production without being structurally related to EPO protein.
Approved in China in 2023 for CKD-associated anemia, pegmolesatide immediately became an anti-doping concern. Liu et al. (2025) developed the first validated detection method using EPO receptor-coupled magnetic nanoparticles to isolate pegmolesatide from blood samples, followed by trypsin digestion and nanoLC-Q/Orbitrap mass spectrometry to identify characteristic peptide fragments.[1]
This detection approach, using the biological receptor as an affinity capture agent, represents a new strategy that may become standard for detecting PEGylated peptide drugs. Traditional antibody-based methods that work for recombinant EPO cannot detect pegmolesatide because it has no structural similarity to the EPO protein. For the history of EPO as the peptide that defined endurance doping, each generation of EPO-mimetic has required new detection technology.
Designer Modifications: Glycine Swaps and D-Amino Acids
Perhaps the most concerning emerging threat is the deliberate modification of known peptide sequences to evade detection panels. WADA-accredited laboratories have identified seized doping materials containing growth hormone secretagogues with glycine substitutions at key positions, creating novel analogs that maintain biological activity while producing different mass spectrometry fragmentation patterns than the reference standards in screening databases.[2]
Common modification strategies include: replacing L-amino acids with D-amino acids (increasing resistance to enzymatic degradation and extending half-life), adding PEG chains (increasing molecular weight beyond typical screening ranges), N-terminal acetylation (as seen with TB-500, which is the N-acetylated form of the thymosin beta-4 active fragment), and truncating or extending peptide sequences while preserving the receptor-binding region.
These modifications create an endless cat-and-mouse dynamic. For each new analog, anti-doping laboratories must synthesize reference standards, characterize fragmentation patterns, validate detection methods, and implement them in routine screening. This process takes months to years per compound.
Detection Technology: A Decade of Progress
Judak et al. (2021) reviewed a decade of progress in doping control analysis of small peptides, documenting how LC-MS-based methodologies have been drastically simplified while maintaining performance. High-resolution mass spectrometers (Q-Orbitrap, Q-TOF) have become the standard detection platform, replacing lower-resolution triple quadrupole instruments. The discovery and implementation of metabolite/catabolite detection has extended detection windows for several peptides, improving analytical retrospectivity.[3]
Gomez-Guerrero et al. (2022) reviewed how synthetic peptides serve as reference standards, internal standards, and metabolite analogs in doping control. Solid-phase peptide synthesis (SPPS) provides the custom peptide standards that laboratories need for method development, but each new target peptide or analog requires a dedicated synthesis campaign.[4]
For the technical details of how mass spectrometry and biomarker testing detect peptide doping, the analytical chemistry is the backbone of anti-doping enforcement.
TB-500 and Thymosin Beta-4: The Detection Challenge
TB-500 (N-acetylated LKKTETQ) is a synthetic fragment of thymosin beta-4 that is widely used in horse racing and increasingly in human athletics for its purported wound healing and anti-inflammatory properties. Ho et al. (2012) developed the first detection method capable of identifying TB-500 at 0.02 ng/mL in plasma and 0.01 ng/mL in urine using solid-phase extraction followed by LC-MS.[5]
The metabolite profiling was crucial: in addition to the parent peptide, the method detected multiple metabolites that extend the detection window beyond what parent-only testing would achieve. Endogenous thymosin beta-4 is naturally present in all nucleated cells, but TB-500 is a specific synthetic fragment with an artificial N-acetylation that does not occur naturally at this position, providing a clean analytical distinction between natural and exogenous exposure.
For TB-500's pharmacology and research profile, the peptide's therapeutic interest coexists with its doping prohibition.
Ibutamoren (MK-677): The Oral GH Secretagogue Problem
Ibutamoren is technically not a peptide but a peptidomimetic, a small molecule that mimics the structure and function of the natural peptide ghrelin at the GH secretagogue receptor. It was explicitly added to the WADA Prohibited List as a named example under growth hormone secretagogues. Philip et al. (2022) identified 22 metabolites of ibutamoren (17 phase I and 5 phase II) in equine samples, with major metabolites detectable up to 96 hours after a single oral dose.[6]
The ibutamoren problem illustrates a broader trend: the boundary between peptides and small molecules is blurring. As peptide pharmacology identifies receptor targets, medicinal chemists develop oral small-molecule mimetics that activate the same pathways. These compounds are often easier to obtain, easier to administer (oral vs injectable), and initially harder to detect because they fall outside traditional peptide screening panels. For MK-677's full pharmacological profile, the performance enhancement rationale and the insulin resistance trade-off explain why it attracts both athletes and anti-doping attention.
GHRPs: The Established Threat That Keeps Evolving
Growth hormone releasing peptides (GHRP-1 through GHRP-6, hexarelin, ipamorelin) have been prohibited since WADA first addressed peptide doping. They stimulate growth hormone secretion by binding the ghrelin receptor (GHS-R1a), producing pulsatile GH release that mimics normal physiology. Detection relies on identifying the parent peptides or their metabolites in urine within a narrow window (typically 24-48 hours after administration).
The GHRP family illustrates why the peptide doping threat keeps evolving. The original GHRP-6 is well-characterized and detectable. But modified analogs, hexarelin with altered amino acid sequences, ipamorelin derivatives with non-natural amino acids, continue to emerge from gray-market synthesis. Each modification potentially creates a molecule that passes through existing LC-HRMS screening panels without triggering an alert.
The most recent Thevis annual banned-substance review (2025) documented ongoing research into novel GHRP detection strategies, including metabolite-based approaches that detect downstream products common to multiple GHRP analogs rather than relying on parent compound identification. This metabolite strategy could future-proof detection against some modifications, since the metabolic machinery often produces similar fragments regardless of minor structural changes to the parent peptide.
The Detection Gap
The fundamental problem in peptide anti-doping is temporal. The typical timeline from a new peptide's emergence on the gray market to a validated, implemented detection method in accredited laboratories is 12-36 months. During this window, athletes can use the substance with minimal risk of detection.
Several factors compound this gap: peptides have short detection windows (hours to days for most), urine-based testing is less effective than blood testing for many peptide targets, out-of-competition testing frequency varies dramatically between sports and jurisdictions, and the Athlete Biological Passport approach that detects indirect effects of doping (like GH biomarkers or reticulocyte changes) requires longitudinal data that is not available for all athletes.
The gray-market peptide supply chain, operating through the "for research use only" legal fiction, provides a steady stream of novel compounds that outpaces laboratory method development. This is not a problem that can be solved by faster analytical chemistry alone. It requires intelligence-driven testing (targeting athletes in sports and disciplines where peptide use is likely), better out-of-competition sample collection, and integration of indirect biomarker approaches with direct peptide detection.
The Athlete Biological Passport represents the most promising long-term strategy. Rather than detecting the peptide itself, the passport tracks biomarkers that change when peptides are used: elevated IGF-1 and suppressed GH pulsatility for GH secretagogues, reticulocyte percentage and hemoglobin mass for EPO mimetics, and testosterone/LH ratios for GnRH analogs. These indirect markers are harder to mask, persist longer than the parent peptides, and work regardless of which specific compound within a class was used. But passport programs require longitudinal data collection, statistical modeling for each athlete's individual reference ranges, and institutional commitment to testing frequency that many sports have not achieved.
The scale of the problem is visible in testing statistics: WADA-accredited laboratories analyzed over 300,000 samples in 2023, but adverse analytical findings for peptide hormones and related substances represented only 0.3% of total findings. This low detection rate likely reflects the short detection windows of most peptides rather than low prevalence of use. Prevalence studies using anonymous surveys and indirect methods consistently estimate peptide doping rates several times higher than the adverse analytical finding rate. The gap between estimated prevalence and detected cases is the clearest evidence that current testing infrastructure, despite a decade of analytical progress, remains insufficient for the peptide doping problem. Whether increased testing frequency, dried blood spot collection, or expanded biomarker panels will close this gap remains to be seen.
The Bottom Line
Emerging peptide doping threats include mitochondrial-derived peptides (MOTS-c, added to the 2025 WADA list), next-generation EPO mimetics (pegmolesatide, requiring novel receptor-based detection), and designer modifications of known prohibited peptides (glycine swaps, D-amino acid substitutions, PEGylation). Anti-doping laboratories now screen for 63 peptide-related targets using LC-HRMS, a substantial improvement over a decade ago. Detection methods for specific compounds like TB-500 achieve sensitivities of 0.01-0.02 ng/mL, and metabolite profiling extends detection windows. The primary challenge remains the 12-36 month gap between a new peptide's market emergence and validated detection method implementation, during which athletes face minimal testing risk.